Pendal Group LTD Incyte Corp Transaction History

Pendal Group LTD

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$66.18 - $83.18 $206,283 - $259,272	-3,117 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$66.02 - $79.71 $1.45 Million - $1.75 Million	-21,901 Reduced 87.54%	3,117 $247,000
Q4 2021 Jan 18, 2022	BUY	$63.34 - $74.11 $1.34 Million - $1.57 Million	21,141 Added 545.29%	25,018 $1.84 Million
Q3 2021 Nov 05, 2021	BUY	$68.67 - $84.02 $89,408 - $109,394	1,302 Added 50.56%	3,877 $267,000
Q2 2021 Jul 28, 2021	BUY	$79.87 - $87.53 $205,665 - $225,389	2,575 New	2,575 $217,000
Q2 2020 Aug 07, 2020	SELL	$74.18 - $108.93 $3.46 Million - $5.09 Million	-46,685 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$63.18 - $85.97 $1.54 Million - $2.09 Million	24,364 Added 109.15%	46,685 $0
Q4 2019 Feb 06, 2020	BUY	$73.04 - $95.72 $851,573 - $1.12 Million	11,659 Added 109.35%	22,321 $0
Q3 2019 Nov 12, 2019	SELL	$72.82 - $86.52 $1.17 Million - $1.39 Million	-16,010 Reduced 60.03%	10,662 $0
Q2 2019 Aug 01, 2019	BUY	$73.52 - $88.7 $1.96 Million - $2.37 Million	26,672 New	26,672 $0
Q2 2018 Jul 18, 2018	SELL	$60.85 - $83.98 $200,196 - $276,294	-3,290 Closed	0 $0
Q1 2018 May 08, 2018	SELL	$83.06 - $100.98 $17,193 - $20,902	-207 Reduced 5.92%	3,290 $0
Q4 2017 Feb 06, 2018	BUY	$93.56 - $116.6 $327,179 - $407,750	3,497	3,497 $0

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Pendal Group LTD, based on Form 13F filings with the SEC.

Stay updated on Pendal Group LTD with notifications on news.